Nektar Therapeutics (NKTR) Enterprise Value (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Enterprise Value of -$568.6 million for Q1 2026, down 160.07% year-over-year from $946.5 million in Q1 2025, and down 131.37% quarter-over-quarter from -$245.8 million in Q4 2025.
Nektar Therapeutics (NKTR) Enterprise Value (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$568.6 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 160.07% year-over-year to -$568.6 million; the TTM figure through Mar 2026 stood at -$568.6 million (down 160.07% YoY), while the FY2025 annual figure was -$245.8 million, up 3.71% from the prior year.
- Enterprise Value for Q1 2026 stood at -$568.6 million, down from -$245.8 million in the prior quarter.
- The five-year high for Enterprise Value was -$175.9 million in Q2 2025, with the low at -$667.0 million in Q1 2022.
- The 5-year median for Enterprise Value is -$303.6 million (2023), against an average of -$377.6 million.
- The sharpest annual moves came in 2022 and 2026: Enterprise Value jumped 40.68% in 2022, then slumped 160.07% in 2026.
- Nektar Therapeutics' Enterprise Value stood at -$505.0 million in 2022, then jumped by 39.88% to -$303.6 million in 2023, then climbed by 15.94% to -$255.2 million in 2024, then increased by 3.71% to -$245.8 million in 2025, then tumbled by 131.37% to -$568.6 million in 2026.
- Business Quant data shows NKTR's Enterprise Value at -$568.6 million in Q1 2026, -$245.8 million in Q4 2025, and -$270.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | -568.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -568.60 Mn |
| Dec 31, 2025 | -245.75 Mn |
| Sep 30, 2025 | -270.21 Mn |
| Jun 30, 2025 | -175.90 Mn |
| Mar 31, 2025 | -218.63 Mn |
| Dec 31, 2024 | -255.23 Mn |
| Sep 30, 2024 | -244.50 Mn |
| Jun 30, 2024 | -271.24 Mn |
| Mar 31, 2024 | -289.24 Mn |
| Dec 31, 2023 | -303.62 Mn |
| Sep 30, 2023 | -372.66 Mn |
| Jun 30, 2023 | -409.43 Mn |
| Mar 31, 2023 | -456.83 Mn |
| Dec 31, 2022 | -504.98 Mn |
| Sep 30, 2022 | -546.39 Mn |
| Jun 30, 2022 | -619.32 Mn |
| Mar 31, 2022 | -667.03 Mn |
| Dec 31, 2021 | -733.96 Mn |
| Sep 30, 2021 | -921.08 Mn |
| Jun 30, 2021 | -1.00 Bn |